A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

NCT02335411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: pembrolizumab
DRUG: cisplatin
DRUG: 5-FU
DRUG: capecitabine

Sponsor

Merck Sharp & Dohme LLC